706.20EURMkt Cap: 43.92B EURP/E: 36.40Last update: 2026-05-21
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART fo…
Industry Peers
Biotechnology105.72BDKKP/E 20.3
45.86BEURP/E 30.0
40.12BUSDP/E 75.7
31.57BSEKP/E 46.7
28.21BSEKP/E 133.6
22.19BDKKP/E 3.5
15.05BDKKP/E 13.0
9.25BEURP/E 99.0
loading…
Indicators:|
Key Statistics
Company
Market Cap43.92B EUR
Enterprise Value39.44B EUR
Revenue (TTM)4.74B EUR
Gross Profit3.70B EUR
Net Income (TTM)1.29B EUR
Revenue/Share77.03 EUR
Last Price706.20 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1.9K
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINNL0010832176
Valuation
P/E (Trailing)36.40
P/E (Forward)22.88
PEG1.34
EV/EBITDA29.91
EV/Revenue8.32
P/S9.26
P/B6.93
EPS (TTM)19.40
EPS (Forward)30.86
52W Range
687.0095% of range707.20
52W High707.20 EUR
52W Low687.00 EUR
Profitability
Gross Margin89.15%
Oper. Margin30.01%
EBITDA Margin27.80%
Profit Margin31.11%
ROE17.64%
ROA14.88%
Growth
Revenue Growth62.60%
Earnings Growth114.00%
Cash Flow & Leverage
Operating CF685.19M EUR
CapEx (TTM)111.68M EUR
FCF Margin—
FCF Yield—
Net Debt-4.39B EUR
Net Debt/EBITDA-3.33
Balance Sheet
Debt/Equity0.01
Current Ratio—
Quick Ratio—
Book Value/Sh101.90 EUR
Cash/Share71.54 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)845.01 EUR
Target Range600.00 EUR – 991.00 EUR
# Analysts14
Ownership
Shares Out.62.19M
Float61.96M
Insiders0.00%
Institutions44.32%
Technical
SMA 50658.94 (+7.2%)
SMA 200683.44 (+3.3%)
Beta-0.06
S&P 52W Chg28.31%
Avg Vol (30d)79.82K
Avg Vol (10d)78.21K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—